🇺🇸 FDA
Preview mode — showing bulk-ingested data not yet promoted to production. Hide preview

Drug profile · INN

diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis, hepatitis b (recombinant) and haemophilus influenzae type b conjugate vaccine, adjuvanted

HEXAVAC

J07CA
Patents linked
0
News articles
0

Quick answer

diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis, hepatitis b (recombinant) and haemophilus influenzae type b conjugate vaccine, adjuvanted (HEXAVAC) is an FDA-listed pharmaceutical active ingredient.

Key facts

INN diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis, hepatitis b (recombinant) and haemophilus influenzae type b conjugate vaccine, adjuvanted
Brand HEXAVAC
ATC code J07CA

Frequently asked questions

What is diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis, hepatitis b (recombinant) and haemophilus influenzae type b conjugate vaccine, adjuvanted?

diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis, hepatitis b (recombinant) and haemophilus influenzae type b conjugate vaccine, adjuvanted (HEXAVAC) is an FDA-listed pharmaceutical active ingredient.

What is the brand name for diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis, hepatitis b (recombinant) and haemophilus influenzae type b conjugate vaccine, adjuvanted?

HEXAVAC is a marketed brand name for diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis, hepatitis b (recombinant) and haemophilus influenzae type b conjugate vaccine, adjuvanted. Check FDA Drugs@FDA for the current US label holder and prescribing information.